At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 270 enrolled
Drug / intervention
Doripenemdrug
Likely dose
Doripenem 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Post Marketing Surveillance Study on the Safety and Effectiveness of Doripenem in the Therapy of Thai Patients With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Complicated Urinary Tract Infections
In Brief
A Phase 4 clinical trial evaluating Doripenem for Infection and 5 related conditions. Completed, enrolled 270 participants across 8 sites.
Detailed Summary
The purpose of this study is to assess the safety and efficacy of doripenem in participants with nosocomial pneumonia (inflammation of the lungs in which the lungs become heavy; pneumonia occurring at least 48 hours after hospital admission), complicated intra-abdominal (in belly) infections and complicated urinary tract infections (bladder infections).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfection, Cross Infection, Bacterial Infections, Pneumonia, Ventilator-Associated, Intra-abdominal Infections, Urinary Tract Infections
CountriesThailand
Collaborators--
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2009
First PostedAug 2009
Primary CompletionJul 2010
TodayJul 2026
First PostedAug 26, 2009
Enrollment StartJun 1, 2009
Primary CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 16.8 years ago
Interventions
Doripenemdrug
Doripenem 500 mg will be administered as 1 or 4 hours intravenous infusion, after every 8 hours up to maximum of 14 days.